BridgeMD
New treatment option for Macular Hole
Official title No Endotamponade for Macular Hole Repair: the NEMAR Study
ClinicalTrials.gov ID: NCT06908824
What this study is testing
- What it's testing
- Full-thickness macular hole (MH) is a common sight threatening macular condition with a prevalence of 3.3 per 1000 individuals. Prompt surgical repair of MH is imperative in preventing irreversible vision loss from MH as the majority of patients would experience progressive loss of central vision, often resulting in visual acuity (VA) of 20/200 or worse and the spontaneous closure rate is less than 10%.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age \>= 18 years
- Presence of full thickness macular hole in one eye (defined as full thickness discontinuity of neuro-sensory retina at the macula on optical...
- Able to comply to post-operative posture
- VA ≥0.05 and ≤0.8
You likely can't join if
- Fellow eye enrolled in the study
- Eyes that underwent previous macular surgery
- Presence of maculopathy other than macular hole, epi-retinal membrane or myopic maculopathy. For example, age-related macular degeneration, diabetic...
- Axial length \>/= 28mm or presence of significant myopic chorio-retinal atrophy involving the fovea
- Minimum linear diameter \>/=800µm
- Presence of contraindications to intraocular gas, such as advanced glaucoma or uncontrolled glaucoma
See the full eligibility criteria
- Age \>= 18 years
- Presence of full thickness macular hole in one eye (defined as full thickness discontinuity of neuro-sensory retina at the macula on optical coherence tomography)
- Able to comply to post-operative posture
- VA ≥0.05 and ≤0.8
- Fellow eye enrolled in the study
- Eyes that underwent previous macular surgery
- Presence of maculopathy other than macular hole, epi-retinal membrane or myopic maculopathy. For example, age-related macular degeneration, diabetic macular edema or pre-existing macular scar
- Axial length \>/= 28mm or presence of significant myopic chorio-retinal atrophy involving the fovea
- Minimum linear diameter \>/=800µm
- Presence of contraindications to intraocular gas, such as advanced glaucoma or uncontrolled glaucoma
- Significant macular puckering (Govetto staging ≥ stage 2)
- Patients who are unable to give informed consent
- Patients who are pregnant
The study team makes the final eligibility decision.
Where it's taking place
- Hong Kong, Hong Kong
- Poznan, Poland
- Taoyuan, Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hong Kong, Hong Kong; Poznan, Poland; Taoyuan, Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.